Get the Stockscreener App
5.285
0.28%
-0.015
Kalaris Therapeutics Inc stock is traded at $5.285, with a volume of 5,791.
It is down -0.28% in the last 24 hours and down -15.71% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$5.30
Open:
$5.36
24h Volume:
5,791
Relative Volume:
0.08
Market Cap:
$119.79M
Revenue:
-
Net Income/Loss:
$-43.44M
P/E Ratio:
-1.2598
EPS:
-4.1951
Net Cash Flow:
$-43.18M
1W Performance:
-4.08%
1M Performance:
-15.71%
6M Performance:
+11.73%
1Y Performance:
+10.33%
1-Day Range:
$5.21
$5.365
1-Week Range:
$5.195
$5.73
52-Week Range:
$2.14
$11.88
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
5.2101 | 121.86M | 0 | -43.44M | -43.18M | -4.1951 |
VRTX
Vertex Pharmaceuticals Inc
|
429.11 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.49 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.07 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.49 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.98 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | Morgan Stanley | Overweight |
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Nov-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
View All
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Update - MarketBeat
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know - MSN
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics (NASDAQ: KLRS) outlines 2026 pay and board votes - Stock Titan
Kalaris Therapeutics (NASDAQ:KLRS) Stock Price Down 3.6%What's Next? - MarketBeat
Kalaris Therapeutics (KLRS) Stock: Directional Bias Review | Q4 2025: Better Than ExpectedSocial Flow Trades - Newser
KLRS (Kalaris Therapeutics Inc.) reports narrower Q4 2025 loss than expected, shares post mild gains after earnings release.Hot Momentum Watchlist - Xã Châu Thành
This Dick's Sporting Goods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
KLRS Initiated Coverage by Morgan Stanley -- Rating Set to Overw - GuruFocus
Morgan Stanley Initiates Kalaris Therapeutics at Overweight - marketscreener.com
Morgan Stanley Initiates Kalaris Therapeutics(KLRS.US) With Buy Rating, Announces Target Price $14 - 富途牛牛
Morgan Stanley initiates Kalaris stock with overweight rating By Investing.com - Investing.com India
KLRS SEC FilingsKalaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[EFFECT] Kalaris Therapeutics, Inc. SEC Filing - Stock Titan
Kalaris Therapeutics (NASDAQ: KLRS) registers $100M ATM program with TD Cowen - Stock Titan
Kalaris Therapeutics (NASDAQ: KLRS) registers 5,000,000 shares for resale - Stock Titan
Death Cross: Will Kalaris Therapeutics Inc benefit from rate cuts2026 Macro Moves & Breakout Confirmation Alerts - baoquankhu1.vn
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift - TipRanks
Kalaris Therapeutics IncMatthew Gall resigns as CFO effective April 14, 2026SEC filing - marketscreener.com
CFO exit at Kalaris Therapeutics (NASDAQ: KLRS) as Brett Hagen takes finance lead - Stock Titan
Volume Summary: Is Kalaris Therapeutics Inc attractive for institutional investors2026 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Kalaris Therapeutics (NASDAQ: KLRS) files $350M shelf, $100M ATM - Stock Titan
Kalaris Therapeutics (NASDAQ: KLRS) registers 5.0M shares resale prospectus - Stock Titan
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Growth Value: Should you avoid Kalaris Therapeutics Inc stock right nowQuarterly Performance Summary & Real-Time Stock Entry Alerts - baoquankhu1.vn
KLRS Stock Analysis: Kalaris Therapeutics Inc. Gains 2.86 Percent to Trade at 5.93 Dollars - Xã Thanh Hà
Aug PreEarnings: Can Kalaris Therapeutics Inc weather a recessionShare Buyback & Smart Swing Trading Alerts - baoquankhu1.vn
Bond Watch: Is Kalaris Therapeutics Inc attractive for institutional investors2026 Price Action Summary & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Ideas Watch: Is Kalaris Therapeutics Inc a good stock for dollar cost averagingTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Brett Hagen Sells 1,915 Shares of Kalaris Therapeutics (NASDAQ:KLRS) Stock - MarketBeat
Kalaris Therapeutics (KLRS) CAO sells stock and gets large option grant - Stock Titan
Morgan Stanley lists KLRS restricted stock vesting parcels (KLRS) in Form 144 notice - Stock Titan
Kalaris Therapeutics (KLRS) awards 222,000 stock options to director Andrew Oxtoby - Stock Titan
Kalaris Therapeutics (KLRS) CFO receives grant of 95,000 stock options - Stock Titan
Kalaris Therapeutics (KLRS) grants CMO 135,000 stock options - Stock Titan
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates - VisionMonday.com
Analyst Upgrade: Should you avoid Faraday Future Intelligent Electric Inc stock right nowFed Meeting & Pattern Based Trade Signal System - baoquankhu1.vn
Kalaris Therapeutics 10-K: $0 Revenue, $(0.00) EPS, $(43.4M) Net Loss - TradingView
Kalaris Therapeutics (NASDAQ: KLRS) builds TH103 pipeline in retinal disease - Stock Titan
Kalaris Therapeutics Reports 2025 Financial Results, Highlights Positive TH103 nAMD Phase 1a Data and Strong Cash Position - Minichart
Kalaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
KLRS: Strong clinical progress and $118M cash position support operations through 2027 - TradingView
Kalaris (Nasdaq: KLRS) trims 2025 loss as $118M cash funds TH103 trials - Stock Titan
Retinal drug developer Kalaris posts $43M loss, funded into late 2027 - Stock Titan
Kalaris Therapeutics (NASDAQ:KLRS) Raised to "Hold" at Wall Street Zen - MarketBeat
Raymond James Maintains Strong Buy on KLRS Kalaris Therapeutics Inc Mar 2026 - Meyka
William Blair reiterates Kalaris stock rating on TH103 potential By Investing.com - Investing.com Canada
Kalaris Therapeutics TH103: Next-Generation Anti-VEGF for Retinal Diseases Shows Promising Phase 1a Results and Extended Durability 23578 - Minichart
Stock Market Recap: Can Kalaris Therapeutics Inc weather a recessionPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Raymond James reiterates Strong Buy on Kalaris stock amid trial delay By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Kalaris stock amid trial delay - Investing.com UK
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):